Advanced

Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.

Sjögreen Gleisner, Katarina LU ; Dewaraja, Y K; Chiesa, C; Tennvall, Jan LU ; Lindén, Ola LU ; Strand, Sven-Erik LU and Ljungberg, Michael LU (2011) In Quarterly Journal of Nuclear Medicine and Molecular Imaging 55(2). p.126-154
Abstract
Radioimmunotherapy involves the use of radiolabeled monoclonal antibodies (MAbs) to treat malignancy. The therapeutic effect is determined by the radiopharmaceutical, the radiation absorbed dose and previous treatments. There are currently two approved radiopharmaceuticals for the treatment of B-cell lymphoma - the 90Y-labeled ibritumomab and the 131I-labeled tositumomab. Both are directed against CD20, albeit not against the same epitope. This paper summarizes current results of dose-responses for normal tissues and tumours of [131I]tositumomab and [90Y]ibritumomab tiuxetan, discusses them in the context of dosimetry methods used and highlights the assumptions being made in the different dosimetry methodologies. Moreover, we wish to point... (More)
Radioimmunotherapy involves the use of radiolabeled monoclonal antibodies (MAbs) to treat malignancy. The therapeutic effect is determined by the radiopharmaceutical, the radiation absorbed dose and previous treatments. There are currently two approved radiopharmaceuticals for the treatment of B-cell lymphoma - the 90Y-labeled ibritumomab and the 131I-labeled tositumomab. Both are directed against CD20, albeit not against the same epitope. This paper summarizes current results of dose-responses for normal tissues and tumours of [131I]tositumomab and [90Y]ibritumomab tiuxetan, discusses them in the context of dosimetry methods used and highlights the assumptions being made in the different dosimetry methodologies. Moreover, we wish to point at the possibility of performing low-cost therapy bremsstrahlung imaging for [90Y]ibritumomab tiuxetan to confirm biodistribution, and possibly also for dosimetric calculations. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Lymphoma, Dosimetry, Antibodies, monoclonal, Radioimmunotherapy
in
Quarterly Journal of Nuclear Medicine and Molecular Imaging
volume
55
issue
2
pages
126 - 154
publisher
Edizioni Minerva Medica
external identifiers
  • pmid:21386787
  • wos:000291627700003
  • scopus:79957658685
ISSN
1824-4785
language
English
LU publication?
yes
id
561db951-2dba-47ce-85e2-5501b3c27db7 (old id 1884189)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21386787?dopt=Abstract
date added to LUP
2011-04-01 14:21:40
date last changed
2017-01-01 03:39:20
@article{561db951-2dba-47ce-85e2-5501b3c27db7,
  abstract     = {Radioimmunotherapy involves the use of radiolabeled monoclonal antibodies (MAbs) to treat malignancy. The therapeutic effect is determined by the radiopharmaceutical, the radiation absorbed dose and previous treatments. There are currently two approved radiopharmaceuticals for the treatment of B-cell lymphoma - the 90Y-labeled ibritumomab and the 131I-labeled tositumomab. Both are directed against CD20, albeit not against the same epitope. This paper summarizes current results of dose-responses for normal tissues and tumours of [131I]tositumomab and [90Y]ibritumomab tiuxetan, discusses them in the context of dosimetry methods used and highlights the assumptions being made in the different dosimetry methodologies. Moreover, we wish to point at the possibility of performing low-cost therapy bremsstrahlung imaging for [90Y]ibritumomab tiuxetan to confirm biodistribution, and possibly also for dosimetric calculations.},
  author       = {Sjögreen Gleisner, Katarina and Dewaraja, Y K and Chiesa, C and Tennvall, Jan and Lindén, Ola and Strand, Sven-Erik and Ljungberg, Michael},
  issn         = {1824-4785},
  keyword      = {Lymphoma,Dosimetry,Antibodies,monoclonal,Radioimmunotherapy},
  language     = {eng},
  number       = {2},
  pages        = {126--154},
  publisher    = {Edizioni Minerva Medica},
  series       = {Quarterly Journal of Nuclear Medicine and Molecular Imaging},
  title        = {Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.},
  volume       = {55},
  year         = {2011},
}